Common Questions Asked Regarding Ibrutinib Study

Description: Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology summarizes common questions that are asked regarding the updates study on the RESONATE trial, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study
Shared By : AnnualMeeting2017
Posted on : 06/15/17
Added : 2 years ago